https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53474 Wed 28 Feb 2024 15:13:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50696 Wed 28 Feb 2024 15:12:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47703 Wed 25 Jan 2023 10:34:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36899 Wed 24 Nov 2021 15:53:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34918 Wed 24 Nov 2021 15:53:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31170 Wed 24 Nov 2021 15:50:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35197 Wed 24 May 2023 12:06:57 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51394 Wed 24 Apr 2024 12:04:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48925 Wed 19 Apr 2023 15:49:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31169 Wed 17 Nov 2021 16:32:43 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31167 Wed 17 Nov 2021 16:31:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35239 Wed 17 Nov 2021 16:31:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30657 Wed 17 Nov 2021 16:30:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30882 Wed 17 Nov 2021 16:28:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53433 120 mmHg) in the PMBE group reduced by − 6.46 mmHg (p = 0.001) at 12 weeks compared to baseline. No significant changes were reported for individuals with optimal (≤120 mmHg) SBP nor did DBP significantly change in either study groups. In individuals with non-medicated normal-high SBP, SBP significantly reduced by − 7.49 mmHg (p = 0.001) and DBP by − 3.06 mmHg (p = 0.011) at 12 weeks compared to baseline after PMBE. Cross-group comparisons were not statistically different. Conclusions: A polyphenol-rich dietary supplement derived from PMBE led to a clinically and statistically significant reduction in SBP in adults. Future studies to investigate the effects of PMBE-polyphenol supplementation on BP are warranted to confirm and explore optimal dose and impact on hypertension.]]> Wed 17 Apr 2024 14:49:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47145 Wed 14 Dec 2022 15:27:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47342 Wed 13 Mar 2024 07:50:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50277 90% of clinicians would continue specialist follow-up for at least 5 years. The majority of clinicians felt that patients experienced disproportionate fear of recurrence and were reassured by follow-up. After multivariable analysis, clinicians who participated in multidisciplinary teams (MDTs) were more likely to choose de-escalated care for both initial treatment (p = .005) and follow-up care (>5 years, p = .05). Conclusion: Clinician attitudes captured by this survey reflect recent changes in guidelines towards hemithyroidectomy for low-risk WDTC, particularly amongst MDT attendees. There is a need to further examine the impact of de-escalated care on fear of recurrence and quality of life in thyroid cancer survivors.]]> Wed 12 Jul 2023 16:24:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36123 Wed 12 Feb 2020 15:26:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30921 Wed 11 Apr 2018 14:06:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25769 Wed 11 Apr 2018 13:54:22 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29476 50% ‘green’ items, as assessed via standardised menu audits undertaken by trained dietitians. For each primary outcome, between-group differences were assessed using Fisher’s exact test under an intention to treat approach. Results: There was insufficient evidence to conclude the intervention had a positive impact on the proportion of intervention schools with no ‘red’ or ‘banned’ items on their menu (RR = 2.8; 95% CI: 0.9 to 8.9; p = 0.0895), or on the proportion of intervention schools with more than 50% ‘green’ items (RR = 1.5; 95% CI: 0.7 to 3.2; p = 0.2568). These findings remained non-significant in the multiple imputation analyses. Intervention schools were significantly more likely to have a lower percentage of ‘red’ items (p-value: 0.007) and a higher percentage of ‘green’ items on the menu (p-value: 0.014). This remained statistically significant in the multiple imputation analyses for ‘red items’ (p-value: 0.0081) but not for ‘green’ items (p-value: 0.0910). Conclusions: While there was insufficient statistical evidence to suggest that this multicomponent audit and feedback intervention was effective in improving primary schools’ compliance with a healthy canteen policy, the intervention demonstrated some positive impact in reducing the availability of ‘red’ items on the menu.]]> Wed 11 Apr 2018 11:32:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16808 Wed 11 Apr 2018 10:57:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30590 Wed 11 Apr 2018 10:46:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25128 Wed 11 Apr 2018 10:21:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16803 Wed 11 Apr 2018 10:17:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13926 Wed 11 Apr 2018 09:52:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35488 Wed 10 Nov 2021 15:13:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37857 Wed 10 Nov 2021 15:12:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51823 .80) were good for both PROMIS measures and comparable to or better than all legacy measures. At the recommended mild cut-point (55), PROMIS-A-SF had sensitivity (.67) comparable to or better than all the legacy measures, whereas PROMIS-A-CAT sensitivity (.59) was lower than GAD-7 (.67) and HADS-A (.62), but comparable to PSYCH-6 and higher than DASS-A, DASS-S and DT. Sensitivity for both was.79. A reduced cut-point of 51 on both PROMIS measures improved sensitivity (.83–.84) although specificity was only adequate (.61–.62). Conclusions: The convergent and criterion validity of the PROMIS anxiety measures in cancer populations was confirmed as equivalent, but not superior to, established measures (GAD-7 and HADS-A). The PROMIS-A-CAT did not demonstrate clear advantages over PROMIS-A-SF.]]> Wed 08 May 2024 09:59:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24172 Wed 04 Dec 2019 11:31:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49019 Wed 03 May 2023 12:31:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31148 Wed 02 Oct 2019 10:20:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49758 Tue 30 May 2023 18:03:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39823 Tue 26 Jul 2022 13:52:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31136 Tue 24 Mar 2020 13:00:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31043 Tue 24 Jul 2018 10:12:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31265 Tue 24 Jul 2018 09:52:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38855 Tue 22 Feb 2022 15:26:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44624 P<.0001; with adjustment for infant sex and maternal body mass index). Indigenous mean birthweight percentile was 4.2 units lower (P<.0001). Adjustment for maternal age, smoking, body mass index, and infant sex reduced the difference in birthweight/percentiles to nonsignificance (12 g; P=.07). Conclusion: Disparities exist between indigenous and non-indigenous Australian infants for birthweight, birthweight percentile, and adverse outcome rates. Adjustment for smoking and maternal age removed any significant difference in birthweights and birthweight percentiles for indigenous infants. Our data indicate that birthweight percentiles should not be adjusted for indigenous ethnicity because this normalizes disadvantage; because White and indigenous Australians have diverged for approximately 50,000 years, it is likely that the same conclusions apply to other ethnic groups. The disparities in birthweight percentiles that are associated with smoking will likely perpetuate indigenous disadvantage into the future because low birthweight is linked to the development of chronic noncommunicable disease and poorer educational attainment; similar problems may affect other indigenous populations.]]> Tue 18 Oct 2022 11:09:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41920 0.7. Despite defined cut-off values, no jurisdiction prescribes a reference equation for use; multiple equations exist. We hypothesized that access to subsidized treatment varies depending on the chosen equation. The %FVC and %TLco from different commonly used reference equations across general respiratory patients, and IPF-specific patients, were compared. Methods: FVC and TLco measurements from a large general respiratory laboratory and the Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR) database were analysed using multiple equations. Differences between %FVC and %TLco for each equation were calculated, with particular interest in classification of patients (%) at the threshold for subsidized treatment. Results: A total of 20 378 general respiratory database results were analysed. The %FVC ≥ 50% increased from 86% with the Roca equation to 96% with Quanjer (European Coal and Steal Community, ECSC) and %TLco≥30% increased from 91% with Paoletti to 98% with Thompson. However, overall increase in eligibility for subsidized treatment was modest, varying from 48.2% to 49.2%. A total of 545 AIPFR database results were analysed. The %FVC ≥ 50% increased from 73% with Roca to 94% with Quanjer (ECSC) and %TLco≥30% increased from 87% with Paoletti to 96% with Miller. Overall eligibility for subsidized treatment in the AIPFR group varied from 73.6% to 82.8% between surveyed interstitial lung disease (ILD) centres based entirely on the equation used. Conclusion: Substantial variability exists between reference equations, impacting access to subsidized treatment. Treating clinicians should be aware of this when assessing patients around public funding thresholds.]]> Tue 16 Aug 2022 11:07:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46351 n = 115) and Perth (n = 30), Australia. The Newcastle cohort was enriched with people with asthma (n = 37) and COPD (n = 38). Gene expression for ACE2 and other genes potentially associated with SARS-CoV-2 cell entry was assessed by qPCR, and protein expression was confirmed with immunohistochemistry on endobronchial biopsies and cultured AEC. Results: Increased gene expression of ACE2 was associated with older age (P = 0.03) and male sex (P = 0.03), but not with pack-years smoked. When we compared gene expression between adults with asthma, COPD and healthy controls, mean ACE2 expression was lower in asthma patients (P = 0.01). Gene expression of furin, a protease that facilitates viral endocytosis, was also lower in patients with asthma (P = 0.02), while ADAM-17, a disintegrin that cleaves ACE2 from the surface, was increased (P = 0.02). ACE2 protein expression was also reduced in endobronchial biopsies from asthma patients. Conclusion: Increased ACE2 expression occurs in older people and males. Asthma patients have reduced expression. Altered ACE2 expression in the lower airway may be an important factor in virus tropism and may in part explain susceptibility factors and why asthma patients are not over-represented in those with COVID-19 complications.]]> Tue 15 Nov 2022 15:15:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43079 Tue 13 Sep 2022 12:12:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47057 Tue 13 Dec 2022 15:32:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38509 Tue 12 Oct 2021 15:53:00 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52391 Tue 10 Oct 2023 14:47:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39116 Tue 10 May 2022 15:01:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37736 Tue 08 Aug 2023 10:33:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29230 Tue 05 Jul 2022 14:13:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33554 Tue 04 Jun 2019 15:39:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34984 Tue 03 Sep 2019 18:01:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33661 Tue 03 Sep 2019 18:01:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30581 Tue 01 May 2018 08:51:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31142 Thu 31 May 2018 11:46:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30598 Thu 28 Oct 2021 13:05:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34050 Thu 28 Oct 2021 13:03:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34938 Thu 28 Oct 2021 12:36:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45371 Thu 27 Oct 2022 15:11:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44843 Thu 27 Oct 2022 12:38:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37872 Thu 27 May 2021 15:52:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45682 Thu 25 Jan 2024 14:40:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46513 Thu 24 Nov 2022 15:43:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39156 2 (1, n = 19; 19.0, p = 0.392)). Inter-rater agreement for the modified 81-item Home-CookERI™ was almost-perfect to perfect for 46% of kitchen items (n = 37 items, κ = 0.81–1), moderate to substantial for 28% (n = 23, κ = 0.51–0.8), slight to fair for 15% (n = 12, κ = 0.01–0.5), and chance or worse for 11% of items (n = 9, κ ≤ 0.0). Home-CookERITM was further optimized by reduction to a 77-item version, which is now available to researchers. Conclusion: Home-CookERI™ is a comprehensive tool for quantifying Australian household cooking environments. It has excellent face and content validity and moderate to perfect inter-rater agreement for almost three-quarters of included kitchen items. To expand Home-CookERI™ applications, a home occupant self-completion version is planned for validation.]]> Thu 19 May 2022 16:29:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36905 Thu 16 Jul 2020 12:19:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34467 -1.min^-1) underwent a clinical evaluation of known risk factors by a physician and comprehensive laboratory analysis of immune responses both at rest and after two cycling ergometer tests: 60 min at 65% VO₂max (LONG); and 6 x 3 min intervals at 90% VO₂max (INTENSE). Blood tests were performed to determine Epstein Barr virus (EBV) status and DNA was genotyped for a panel of cytokine gene polymorphisms. Saliva was collected for measurement of IgA and detection of EBV DNA. Athletes were then followed for 9 months for self-reported episodes of respiratory illness, with confirmation of the underlying cause by a sports physician. There were no associations with risk of respiratory illness identified for any parameter assessed in the clinical evaluations. The laboratory parameters associated with an increased risk of respiratory illnesses in highly-trained athletes were cytokine gene polymorphisms for the high expression of IL-6 and IFN-γ expression of EBV-DNA in saliva; and low levels of salivary IgA concentration. A genetic risk score was developed for the cumulative number of minor alleles for the cytokines evaluated. Athletes prone to recurrent respiratory illness were more likely to have immune disturbances that allow viral reactivation, and a genetic predisposition to pro-inflammatory cytokine responses to intense exercise.]]> Thu 14 Mar 2019 16:50:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48866 Thu 13 Apr 2023 10:01:04 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38626 Thu 09 Dec 2021 14:48:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31500 Thu 04 Nov 2021 10:39:18 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31171 Thu 02 Feb 2023 15:48:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46836 Thu 01 Dec 2022 15:01:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13951 Sat 24 Mar 2018 10:41:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17373 Sat 24 Mar 2018 08:01:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19672 Sat 24 Mar 2018 08:01:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18447 50 years, showing a rapid increase in the rates of CIS from 2001. * There was an 11% (P = 0.04) and 14% (P = 0.02) annual increase in incidence of CIS in men and women and these rates increased with age. Conclusions * National data (AIHW) substantially underestimate the incidence of CIS in the Australian population. * Patient level data suggest CIS rates are rapidly increasing in Australia despite high treatment rates. * Closer surveillance and awareness of these high rates warrants further study and we recommend that CIS be considered a reportable disease.]]> Sat 24 Mar 2018 07:59:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17220 Sat 24 Mar 2018 07:59:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19389 Sat 24 Mar 2018 07:52:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29906 P=0.42) and vegetable (P=0.17) intakes between HCFV and LCFV groups. Dietary alpha carotene, beta carotene, lutein, and beta cryptoxanthin intakes were significantly different between the two groups (P<0.01). Following HCFV there was a significantly greater increase in skin yellowness (b*) in both sun-exposed (P<0.001) and unexposed areas, (P<0.001), with no change in skin lightness (L*) or redness (a*). Significantly higher plasma alpha carotene (P=0.004), beta carotene (P=0.001), and lutein (P=0.028) concentrations were found following the HCFV intervention. Skin yellowness correlated with alpha carotene and beta carotene. Conclusions: Skin yellowness (b*) and fasting plasma carotenoid concentrations were significantly higher following HCFV than LCFV over 4 weeks.]]> Sat 24 Mar 2018 07:40:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27265 Sat 24 Mar 2018 07:34:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29806 p<0.002; 0.05/25), with a nominal p-value considered as suggestive evidence. For SNPs with evidence of replication, effects on the expression levels of nearby genes in lung tissue were tested in 1,111 lung samples (Lung eQTL consortium), with further functional investigation performed using public epigenomic profiling data (ENCODE). Results: NCOR2-rs12708369 showed strong replication in children (p = 0.0002), with replication unavailable in adults due to low imputation quality. This intronic variant is in a strong transcriptional enhancer element in lung fibroblasts, but its eQTL effects could not be tested due to low imputation quality in the eQTL dataset. SERPINE2-rs6754561 replicated at nominal level in both adults (p = 0.036) and children (p = 0.045), while WNT16-rs2707469 replicated at nominal level only in adults (p = 0.026). The eQTL analyses showed association of WNT16-rs2707469 with expression levels of the nearby gene CPED1.We found no statistically significant eQTL effects for SERPINE2-rs6754561. Conclusions: We have identified a new gene, NCOR2, in the retinoic acid signalling pathway pointing to a role of vitamin A metabolism in the regulation of FVC. Our findings also support SERPINE2, a COPD gene with weak previous evidence of association with FVC, and suggest WNT16 as a further promising candidate.]]> Sat 24 Mar 2018 07:30:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23722 Sat 24 Mar 2018 07:16:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24253 Sat 24 Mar 2018 07:15:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23033 Sat 24 Mar 2018 07:13:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37590 Mon 29 Mar 2021 10:17:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38996 n 5324), without CVD, hypertension and diabetes at baseline (2001), with complete FFQ data. Results: There were 1342 new cases of hypertension and 629 new cases of non-fatal CVD over 15 years of follow-up. Multivariate analysis indicated that women reporting better adherence to the ARFS (≥38/74) had 15 % (95 % CI 1, 28 %; P = 0·05) lower odds of hypertension and 46 % (95 % CI 6, 66 %; P = 0·1) lower odds of non-fatal CVD. Women reporting better adherence to the MDS (≥8/17) had 27 % (95 % CI 15, 47 %; P = 0·0006) lower odds of hypertension and 30 % (95 % CI 2, 50 %; P = 0·03) lower odds of non-fatal CVD. Conclusions: Better adherence to diet quality scores is associated with lower risk of hypertension and non-fatal CVD. These results support the need for updated evidenced based on the ADG as well as public health nutrition policies in Australia.]]> Mon 29 Jan 2024 17:54:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33273 2+ release, leading to sarcoplasmic reticulum Ca²⁺ depletion, reduced cardiac function, and providing cell protection against ischemia-reperfusion injury. Anesthetic activation of ryanodine receptor 2 is poorly defined, leaving aspects of the protective mechanism uncertain. Methods: Ryanodine receptor 2 from the sheep heart was incorporated into artificial lipid bilayers, and their gating properties were measured in response to five halogenated anesthetics. Results: Each anesthetic rapidly and reversibly activated ryanodine receptor 2, but only from the cytoplasmic side. Relative activation levels were as follows: halothane (approximately 4-fold; n = 8), desflurane and enflurane (approximately 3-fold,n = 9), and isoflurane and sevoflurane (approximately 1.5-fold, n = 7, 10). Half-activating concentrations (Kₐ) were in the range 1.3 to 2.1 mM (1.4 to 2.6 minimum alveolar concentration [MAC]) with the exception of isoflurane (5.3 mM, 6.6 minimum alveolar concentration). Dantrolene (10 µM with 100 nM calmodulin) inhibited ryanodine receptor 2 by 40% but did not alter the Kₐ for halothane activation. Halothane potentiated luminal and cytoplasmic Ca²⁺ activation of ryanodine receptor 2 but had no effect on Mg²⁺ inhibition. Halothane activated ryanodine receptor 2 in the absence and presence (2 mM) of adenosine triphosphate (ATP). Adenosine, a competitive antagonist to ATP activation of ryanodine receptor 2, did not antagonize halothane activation in the absence of ATP. Conclusions: At clinical concentrations (1 MAC), halothane desflurane and enflurane activated ryanodine receptor 2, whereas isoflurane and sevoflurane were ineffective. Dantrolene inhibition of ryanodine receptor 2 substantially negated the activating effects of anesthetics. Halothane acted independently of the adenine nucleotide-binding site on ryanodine receptor 2. The previously observed adenosine antagonism of halothane activation of sarcoplasmic reticulum Ca²⁺ release was due to competition between adenosine and ATP, rather than between halothane and ATP.]]> Mon 24 Sep 2018 13:26:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49545 Mon 22 May 2023 08:45:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24879 Mon 20 Mar 2023 12:52:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39754 Mon 20 Jun 2022 12:01:11 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43000 Mon 18 Sep 2023 11:13:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36898 Fri 21 Jan 2022 09:24:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50835 Fri 18 Aug 2023 10:27:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39651 Fri 17 Jun 2022 13:19:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44472 Fri 14 Oct 2022 08:43:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49387 60 years old and accepted onto the National Organ Matching Service. This RKT Group was divided into donor renal cancers ≤30 mm and >30–≤50 mm. Adverse event profiles for RKT recipients were compared with 22 standard live donor recipients using logistic regression analyses. Recipient and transplant survivals for RKT were compared with 2050 controls from Australian New Zealand Dialysis Transplant Registry using Cox regression models. To increase statistical power for survival analyses, data from 25 RKT recipients from Princess Alexandra Hospital, Brisbane were added, thus creating 48 RKT recipients.Results: There were no significant differences in mortality, transplant failure nor AEs between the 2 cancer Groups. RKT increased the risks of Adverse event profiles (odds ratio: 6.48 [2.92–15.44]; P < 0.001). RKT reduced mortality risk by 30% (hazard ratio [HR]: 0.70 [0.36–1.07]; P = 0.299) compared with those continuing on the transplant list who may or may not be transplanted. RKT significantly reduced mortality risk for those remaining on dialysis (HR: 2.86 [1.43–5.72]; P = 0.003). Transplant survival for RKT was reduced compared with control deceased donor (HR: 0.42 [0.21–0.83]; P = 0.013) and live donor transplants (HR: 0.33 [0.02–0.86]; P =0.023).Conclusions:The use of larger carefully selected cancer-resected kidneys for transplantation appears safe and effective. RKT confers a possible survival advantage compared with waiting for transplantation, an increased survival compared with those remaining on dialysis but reduced transplant survival.]]> Fri 12 May 2023 14:27:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49366 Fri 12 May 2023 12:42:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38429 p = 0.04, ROC AUC 0.90) and standard deviation (SD) (p = 0.02, ROC AUC 0.90), week 2 skewness (p = 0.02, ROC AUC 0.91) and SD (p = 0.01, ROC AUC 0.94), week 4 kurtosis (p = 0.01, AUC 0.92) and SD (p = 0.01, ROC AUC 0.96). Changes in minimum ADC between baseline and week 2 (p = 0.02, ROC AUC 0.94) and baseline and week 4 (p = 0.02, ROC AUC 0.94) were prognostic for local recurrence. For prediction of any recurrence, ADC minimum (p = 0.02, ROC AUC 0.87) and SD (p = 0.01, ROC AUC 0.85) at baseline, and ADC maximum (p = 0.03, ROC AUC 0.77) and SD (p = 0.02, ROC AUC 0.81) at week 4 were significant. On LASSO logistic regression, ADC minimum and SD at baseline were retained for any recurrence. The only significant finding for DCE-MRI was a correlation of k-trans min at the second follow-up with local recurrence (p = 0.05, AUC 0.84). Conclusion: Several ADC parameters at various time points correlate with recurrence suggesting DW-MRI is a potential biomarker for SCCAC.]]> Fri 10 Sep 2021 12:16:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38253 Fri 03 Sep 2021 14:46:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30423 Fri 03 Dec 2021 10:34:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32540 Fri 03 Dec 2021 10:32:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51351 Fri 01 Sep 2023 13:36:25 AEST ]]>